ASTRAZENECA DRN

The FDA revoked the emergency use authorization for AstraZeneca's Evusheld due to its expired shelf life and lack of patient administration approval for over a year.

AstraZeneca has withdrawn its EU marketing application for datopotamab deruxtecan for lung cancer, but continues with its breast cancer application and ongoing clinical trials.